Articles In Press
Back to the articles list |
Back to browse issues page
1- Department of Medical Laboratory Sciences, School of Paramedical, Kermanshah University of Medical Sciences, Kermanshah, Iran
2- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences
4- Department of Molecular Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran ,maleki.hem@gmail.com
2- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences
4- Department of Molecular Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran ,
Abstract: (329 Views)
Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia characterized by the t(15;17) translocation, generating the PML-RARA fusion gene. This fusion occurs in three primary variants: bcr1, bcr2, and bcr3. In Iran, bcr1 is the most prevalent (~73%), bcr3 accounts for ~27%, and bcr2 is virtually undetected. Given this distribution, developing a locally optimized method for detecting bcr1 is essential for accurate and rapid identification of this fusion and crucial for monitoring patient response.
Methods: A synthetic 130-bp PML-RARA bcr1 fragment was cloned into pUC57, and insertion was analyzed by digestion with XbaI and HindIII and agarose gel electrophoresis. RNA from APL patient samples was reverse-transcribed into cDNA, serving as a template for reverse-transcription quantitative polymerase chain reaction (RT-qPCR) with PML-RARA-specific primers and β-actin as the reference. Each run included APL samples, plasmid-based positive controls, healthy negative controls, and no-template controls. Amplification and melt-curve analysis confirmed assay specificity and reproducibility.
Results: The recombinant pUC57-PML-RARA plasmid was verified by XbaI/HindIII digestion. RT-qPCR showed specific amplification of PML-RARA in plasmid controls (Ct 15-20) and APL patient samples (Ct 22-26), with no amplification in negative controls. Melt curve analysis showed single, sharp peaks, confirming specificity, and agarose gel electrophoresis verified the expected product sizes. Relative quantification indicated approximately 26-fold higher expression in plasmid controls compared to patient samples, with high reproducibility at a 1:20 dilution.
Conclusion: This preliminary assessment shows sufficient specificity and reliability for detecting the PML-RARA bcr1 variant, providing a foundation for further validation in the future.
Methods: A synthetic 130-bp PML-RARA bcr1 fragment was cloned into pUC57, and insertion was analyzed by digestion with XbaI and HindIII and agarose gel electrophoresis. RNA from APL patient samples was reverse-transcribed into cDNA, serving as a template for reverse-transcription quantitative polymerase chain reaction (RT-qPCR) with PML-RARA-specific primers and β-actin as the reference. Each run included APL samples, plasmid-based positive controls, healthy negative controls, and no-template controls. Amplification and melt-curve analysis confirmed assay specificity and reproducibility.
Results: The recombinant pUC57-PML-RARA plasmid was verified by XbaI/HindIII digestion. RT-qPCR showed specific amplification of PML-RARA in plasmid controls (Ct 15-20) and APL patient samples (Ct 22-26), with no amplification in negative controls. Melt curve analysis showed single, sharp peaks, confirming specificity, and agarose gel electrophoresis verified the expected product sizes. Relative quantification indicated approximately 26-fold higher expression in plasmid controls compared to patient samples, with high reproducibility at a 1:20 dilution.
Conclusion: This preliminary assessment shows sufficient specificity and reliability for detecting the PML-RARA bcr1 variant, providing a foundation for further validation in the future.
Keywords: Key words: Acute Promyelocytic Leukemia (APL), PML-RARA fusion, bcr1 variant, Translocation t (15, 17)
Type of Study: Original Research Article |
Subject:
Medical Biology
Received: 2025/11/13 | Accepted: 2025/12/6
Received: 2025/11/13 | Accepted: 2025/12/6
References
1. Dozzo A, Galvin A, Shin J-W, Scalia S, O'Driscoll CM, Ryan KB. Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern. Drug Deliver Transl Res. 2023;13(8):2110-41. [DOI:10.1007/s13346-022-01189-4] [PMID] [PMCID]
2. di Masi A, Cilli D, Berardinelli F, Talarico A, Pallavicini I, Pennisi R, et al. PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL. Cell Death Dis. 2016;7(7):e2308-e. [DOI:10.1038/cddis.2016.115] [PMID] [PMCID]
3. Dai B, Wang F, Wang Y, Zhu J, Li Y, Zhang T, et al. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα. Cell Death Differ. 2023;30(5):1320-33. [DOI:10.1038/s41418-023-01139-8] [PMID] [PMCID]
4. Delikkaya B, Morton A, Mikkilineni S, Gong J, Liu J. Beyond the Surface: Uncovering the PML: RARA fusion in cytogenetically cryptic and FISH-negative acute promyelocytic leukemia-A case report and review of the literature. Am J Clin Pathol. 2024;162(Supplement_1):S23-S4. [DOI:10.1093/ajcp/aqae129.051]
5. Rasekh EO, Elsayed GM, Madney Y, El Gammal MM. Prognostic significance of bcr-1 and bcr-3 isoforms of PML-RARA and FLT3-ITD in patients with acute promyelocytic leukemia. Clin Lymph Myeloma Leukem. 2020;20(3):156-67. [DOI:10.1016/j.clml.2019.08.006] [PMID]
6. Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016;95(5):673-80. [DOI:10.1007/s00277-016-2622-1] [PMID]
7. Siahbani S, Safaei A, Faghih M, Hosseini M, Fendereski A, Valibeigi B, et al. Different isoforms of PML-RARA chimeric protein in patients with acute promyelocytic leukemia: survival analysis per demographic characteristics, clinicohematological parameters, and cytogenetic findings. Iran J Pathol. 2023;18(4):456. [DOI:10.30699/ijp.2023.2007229.3145] [PMID] [PMCID]
8. de Almeida TD, Evangelista FCG, Sabino AdP. Acute Promyelocytic Leukemia (APL): A review of the classic and emerging target therapies towards molecular heterogeneity. Future Pharmacol. 2023;3(1). [DOI:10.3390/futurepharmacol3010012]
9. Testa U, Pelosi E. Function of PML-RARA in Acute Promyelocytic Leukemia. Adv Exp Med Biol. 2024;1459:321-39. [DOI:10.1007/978-3-031-62731-6_14] [PMID]
10. Guijarro F, Garrote M, Villamor N, Colomer D, Esteve J, López-Guerra M. Novel tools for diagnosis and monitoring of AML. Curr Oncol. 2023;30(6):5201-13. [DOI:10.3390/curroncol30060395] [PMID] [PMCID]
11. Gonzales PR, Mikhail FM. Diagnostic and prognostic utility of fluorescence in situ hybridization (FISH) analysis in acute myeloid leukemia. Curr Hematol Malig Rep. 2017;12(6):568-73. [DOI:10.1007/s11899-017-0426-6] [PMID] [PMCID]
12. Handschuh L, Kaźmierczak M, Milewski MC, Góralski M, Łuczak M, Wojtaszewska M, et al. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and-M2 through boutique microarrays, real-time PCR and droplet digital PCR. Int J Oncol. 2018;52(3):656-78. [DOI:10.3892/ijo.2017.4233] [PMID] [PMCID]
13. Pessoa FMCdP, de Oliveira MB, Barreto IV, Machado AKdC, Oliveira DSd, Ribeiro RM, et al. Nested-PCR vs. RT-qPCR: A sensitivity comparison in the detection of genetic alterations in patients with acute leukemias. DNA. 2024;4(3):285-99. [DOI:10.3390/dna4030019]
14. Chen Z, Tong Y, Li Y, Gao Q, Wang Q, Fu C, et al. Development and validation of a 3-Plex RT-qPCR assay for the simultaneous detection and quantitation of the three PML-RARa fusion transcripts in acute promyelocytic leukemia. PLoS One. 2015;10(3):e0122530. [DOI:10.1371/journal.pone.0122530] [PMID] [PMCID]
15. Aziz N, Nabi W, Khan M, Gulzar AHB, Rath S, Cheema AAA, et al. Analyzing two decades of leukemia mortality in the US (1999-2020). Clin Lymph Myeloma Leukem. 2025. [DOI:10.2139/ssrn.5125685]
16. Santamaría C, Chillon Santos MdC, Fernández C, Martín-Jiménez P, Balanzategui A, Garcia Sanz R, et al. Using quantification of the PML-RAR transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica. 2007;92(3):315-22. [DOI:10.3324/haematol.10734] [PMID]
17. Wu Q, Zhang R, Fu Y, Zhang J, Chen K, Li J. External quality assessment for PML-RARα detection in acute promyelocytic leukemia: Findings and summary. J Clin Lab Anal. 2019 ;33(6):e22894. [DOI:10.1002/jcla.22894] [PMID] [PMCID]
18. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH,et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2009;113(9):1875-91. [DOI:10.1182/blood-2008-04-150250] [PMID]
19. Scalzulli E, Costa A, Carmosino I, Musiu P, Bisegna ML, De Propris MS, et al. Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time. An Hematol. 2024;103(12):5377-86. [DOI:10.1007/s00277-024-06014-1] [PMID] [PMCID]
20. Brunetti C, Anelli L, Zagaria A, Minervini A, Minervini CF, Casieri P, et al. Droplet digital PCR is a reliable tool for monitoring minimal residual disease in acute promyelocytic leukemia. J Molec Diag. 2017;19(3):437-44. [DOI:10.1016/j.jmoldx.2017.01.004] [PMID]
21. Kim MJ, Cho SY, Lee WI, Park TS, Lee HJ. The utility of the multiplex reverse transcriptase-polymerase chain reaction assay in the detection of hematologic malignancies. Ann Lab Med. 2013;33(4):304-7. [DOI:10.3343/alm.2013.33.4.304]
22. Tran VT, Phan TT, Mac HP, Tran TT, Ho TT, Pho SP,et al. The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia. BMC Res Notes. 2020 ;13(1):394. [DOI:10.1186/s13104-020-05235-7] [PMID] [PMCID]
23. Chatterjee T, Gupta S, Sharma S, Ganguli P. Distribution of different PML/RARα bcr isoforms in Indian Acute Promyelocytic Leukemia (APL) patients and clinicohematological correlation. Mediterr J Hematol Infect Dis. 2014;6(1): e2014004. [DOI:10.4084/mjhid.2014.004] [PMID] [PMCID]
24. Rabade N, Raval G, Chaudhary S, Subramanian P, Kodgule R, Joshi S, et al. Molecular heterogeneity in acute promyelocytic leukemia-a single center experience from India. Medit J Hematology and Infect Dis. 2018;10(1):e2018002. [DOI:10.4084/mjhid.2018.002] [PMID] [PMCID]
25. Xue B, Zhang H, Yan X, Su X, Zhou Y, Xie J, et al. A TaqMan qPCR for precise detection and quantification of diarrheagenic Escherichia coli. Sci Rep. 2025;15(1):16728. [DOI:10.1038/s41598-025-96960-1] [PMID] [PMCID]
26. Abbasi H, Nikoo HR, Fotouhi F, Khosravi A. Development of a robust TaqMan probe-based one-step multiplex RT-qPCR for simultaneous detection of SARS-CoV-2 and Influenza A/B viruses. BMC Microbiol. 2023;23(1):335. [DOI:10.1186/s12866-023-03048-9] [PMID] [PMCID]
27. Taylor SC, Nadeau K, Abbasi M, Lachance C, Nguyen M, Fenrich J. The ultimate qPCR experiment: producing publication quality, reproducible data the first time. Trend Biotechnol. 2019;37(7):761-74. [DOI:10.1016/j.tibtech.2018.12.002] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |